Education
About Us
Working with TipRanks
Follow Us
OS Therapies Incorporated (OSTX)
XASE:OSTX
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.12 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)429.55K
Market Cap
$53.17M
Enterprise Value$51.30M
Total Cash (Recent Filing)$1.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Apr 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding35,214,350
10 Day Avg. Volume265,192
30 Day Avg. Volume429,548
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)110.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.27
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-214.15
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$11.50Price Target Upside698.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$12.80M
Bulls Say, Bears Say
Bulls Say
Improved Capital Structure (zero Debt)Zero reported debt reduces fixed financial obligations and bankruptcy risk, giving management structural flexibility to prioritize clinical development and regulatory work. Positive equity after prior deficits signals recapitalization that supports operations over the medium term.
Fresh Financing Extends Runway Into 2027The $7.53M warrant-inducement proceeds materially extend runway, funding OST‑HER2 regulatory filings, commercial preparation and a proposed OS Animal Health spinoff. Securing multi-quarter funding raises the probability of reaching key clinical/regulatory milestones without immediate distress financing.
Focused Clinical-stage Pipeline In OsteosarcomaA concentrated R&D focus on immunotherapy for osteosarcoma (OST‑HER2) creates specialist expertise, clearer go-to-market strategy and potential first-mover advantages in a niche oncology indication. This structural focus can attract partners and streamline development efforts over months.
Bears Say
No Revenue And Deeply Negative ProfitabilityAbsence of commercial revenue means the business is entirely funding operations through capital markets. Deepening losses erode the modest equity base and increase reliance on future financings, creating persistent financial vulnerability until clinical success or partnering occurs.
Sustained Cash Burn (~-$13M TTM)A ~-$13M TTM cash burn implies recurring external funding needs to sustain development programs. Even with recent proceeds, this structural negative cash flow constrains the firm’s optionality and raises the risk that future rounds, asset sales, or program cuts will be required absent milestone-driven inflows.
Dilution Risk From Warrant RestructuringThe warrant inducement lowered exercise prices and issued new long-dated warrants, which, while raising near-term liquidity, structurally increases potential share dilution and investor overhang. This financing profile can pressure existing holders and limit upside per share across future financings.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.12 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $53.17M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Apr 06, 2026 which is in 30 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.122 by -$0.088.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.14.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 35,214,350 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.122. Following the earnings report the stock price went down -1.099%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (698.61% Upside)
$11.50 (698.61% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.58%
12-Months-Change
Fundamentals
Return on Equity
-914.04%
Trailing 12-Months
Asset Growth
352.81%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$11.50
▲(698.61% Upside)
Technical Analysis
Ownership Overview
18.37% Insiders
0.81% Mutual Funds
1.35% Other Institutional Investors
78.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---